Search Results - "HASSLACHER, C"

Diabetic kidney disesase by Hasslacher, C, Wolf, G, Kempe, P, Ritz, E

Get more information

Antidiabetische Therapie bei Niereninsuffizienz by Hasslacher, C.

“…Zusammenfassung Eine gute Stoffwechselführung beeinflusst die renale und die Lebensprognose des Patienten mit Diabetes mellitus bei Vorliegen einer…”
Get full text

Effect of insulin analogs on the decline of hemoglobin in diabetic patients with nephropathy by Hasslacher, C, Collenberg, E, Möcks, J

“…Decrease of hemoglobin occurs in diabetic patients with nephropathy earlier than in nondiabetic patients, probably due to impaired synthesis of erythropoietin…”
Get more information

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment by SCHUMACHER, S, ABBASI, I, WEISE, D, HATORP, V, SATTLER, K, SIEBER, J, HASSLACHER, C

“…The primary objective of this single-centre, open-label, parallel-group study was to evaluate the pharmacokinetics and safety profile of the prandial glucose…”
Get full text

Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients by Werle, E, Fiehn, W, Hasslacher, C

“…Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. E Werle , W Fiehn and C Hasslacher Central Laboratory,…”
Get full text

Clinical significance of microalbuminuria and evaluation of the Micral-Test by Hasslacher, C

“…Microalbuminuria is defined as excretion of albumin between 20 and 200 micrograms/min. Persistent microalbuminuria indicates a high probability of damage to…”
Get more information

Metabolische Kontrolle bei diabetischer Nephropathie by Hasslacher, C.

Get full text

Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: A postmarketing surveillance study by Hasslacher, C.

“…A total of 3463 hypertensive patients with type II diabetes were treated with lisinopril for 3 months. Lisinopril was well tolerated, adverse effects were…”
Get full text

Similar risks of nephropathy in patients with type I or type II diabetes mellitus by Hasslacher, C, Ritz, E, Wahl, P, Michael, C

“…It is commonly assumed that in patients the risks of developing nephropathy and uraemia are high in type I and low in type II diabetes mellitus. Since type II…”
Get more information

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial by Mathieu, Chantal, Dandona, Paresh, Gillard, Pieter, Senior, Peter, Hasslacher, Christoph, Araki, Eiichi, Lind, Marcus, Bain, Stephen C, Jabbour, Serge, Arya, Niki, Hansen, Lars, Thorén, Fredrik, Langkilde, Anna Maria

“…This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct…”
Get full text

Effect of metabolic factors and blood pressure on kidney function in proteinuric Type 2 (non-insulin-dependent) diabetic patients by HASSLACHER, C, BOSTEDT-KIESEL, A, WAHL, P

“…Decline of kidney function with time and its influencing factors were investigated in the present longitudinal study in Type 2 (non-insulin-dependent) diabetic…”
Get full text

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial by Ruilope, Luis M, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Filippatos, Gerasimos, Nowack, Christina, Kolkhof, Peter, Joseph, Amer, Mentenich, Nicole, Pitt, Bertram

“…Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their…”
Get more information

Protection of renal function in diabetics by Hasslacher, C

“…The course of diabetic nephropathy is affected by several factors that can be manipulated. In primary prevention, near normal metabolic control beginning at…”
Get full text

Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria by MOGENSEN, C. E, VIBERTI, G. C, THOMA, J, KUEFER, J, NILSSON, B, GAMBKE, B, MUELLER, P, STEINBISS, J, WILLAMOWSKI, K.-D, PEHEIM, E, KUTTER, D, HASSLACHER, C, HOFMANN, W, RENNER, R, BOJESTIG, M, POULSEN, P. L, SCOTT, G

“…Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. C E Mogensen , G C Viberti , E Peheim…”
Get full text

Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function by HASSLACHER, Christoph

“…Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function Christoph Hasslacher and for the Multinational…”
Get full text

Urinary glycosylated, free and total pyridinoline and free and total deoxypyridinoline in diabetes mellitus by CLOOS, C, WAHL, P, HASSLACHER, C, TRABER, L, KISTNER, M, JURKUHN, K, SCHMIDT-GAYK, H

“…OBJECTIVE Published data on bone metabolism in diabetes mellitus are conflicting. We have measured pyridinium crosslinks, biochemical markers of bone…”
Get full text

Western blotting of NC1 type IV collagen fragments in human plasma by WERLE, E., HAO, L., HASSLACHER, C., FIEHN, W.

“…Collagen IV matrix of glomerular basement membrane may be involved in the development of various renal diseases, e.g. diabetic nephropathy. An immunoblotting…”
Get full text

Diabetic nephropathy: structural-functional relationships by Hasslacher, C

Get more information

Development of diabetic nephropathy in the rat: morphological, functional, and pathophysiological aspects by Hasslacher, C

Get more information

The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats by KOENEN, C, LANG, C, KEMPE, H.-P, WERLE, E, HASSLACHER, C

“…Clinical studies indicate a nephro-protective effect in conjunction with the use of ACE inhibitors. This study's aim was to determine whether ACE inhibitors…”
Get full text